Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand.Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims & Hers stock plunged more than 50% at one point. Is this once-high-flying healthcare stock a smart buy now?Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 diabetes under the brand name Ozempic and for treating weight loss under the brand name Wegovy.Continue reading
What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand.
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims & Hers stock plunged more than 50% at one point. Is this once-high-flying healthcare stock a smart buy now?
Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 diabetes under the brand name Ozempic and for treating weight loss under the brand name Wegovy.
